Evidence map›Paper›PMID 28931682›Full record

ArticleJournal of virology2017

Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.

Rafael Contreras-Galindo, Derek Dube, Koh Fujinaga, Mark H Kaplan, David M Markovitz

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
9.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 49 citations in OpenAlex.

  1. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  2. Article
  3. Article
  4. Approaches to repurposing reverse transcriptase antivirals in cancer.British journal of clinical pharmacology · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rafael Contreras-GalindoDepartment of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA rafaelc@med.umich.edu.
Derek DubeDepartment of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA.
Koh FujinagaUniversity of California at San Francisco, San Francisco, California, USA.
Mark H KaplanDepartment of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA.
David M MarkovitzDepartment of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan–Ann Arbor · USUniversity of California, San Francisco · US

Funding

Replication of Human Endogenous Retroviruses in Modern HumansR01CA144043 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARKOVITZ, DAVID MICHAEL · 2009 to 2013
$6.4M
CXC Chemokines and HIV PathogenesisR01AI062248 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARKOVITZ, DAVID MICHAEL · 2005 to 2009
$1.6M
Human Endogenous Retroviral Sequences, a Tool to Study the Role of Centromeres inK22CA177824 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CONTRERAS, RAFAEL ALEJANDRO · 2013 to 2015
$346k
The Viral Life Cycle of Human Endogenous Retrovirus Type KF32AI106189 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DUBE, DEREK · 2013 to 2014
$66k
NCI NIH HHS K22 CA177824NCI NIH HHS R01 CA144043NIAID NIH HHS F32 AI106189NIAID NIH HHS R01 AI062248
6 · The paper itself

Abstract

Human endogenous retroviruses (HERVs) make up 8% of the human genome. The HERV type K (HERV-K) HML-2 (HK2) family contains proviruses that are the most recent entrants into the human germ line and are transcriptionally active. In HIV-1 infection and cancer, HK2 genes produce retroviral particles that appear to be infectious, yet the replication capacity of these viruses and potential pathogenicity has been difficult to ascertain. In this report, we screened the efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting the enzymatic activity of HK2 RT and HK2 genomic replication. Interestingly, only one provirus, K103, was found to encode a functional RT among those examined. Several nucleoside analogue RTIs (NRTIs) blocked K103 RT activity and consistently inhibited the replication of HK2 genomes. The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT. HIV-1-specific nonnucleoside RTIs (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (IIs) did not affect HK2, except for the NNRTI etravirine (ETV). The inhibition of HK2 infectivity by NRTIs appears to take place at either the reverse transcription step of the viral genome prior to HK2 viral particle formation and/or in the infected cells. Inhibition of HK2 by these drugs will be useful in suppressing HK2 infectivity if these viruses prove to be pathogenic in cancer, neurological disorders, or other diseases associated with HK2. The present studies also elucidate a key aspect of the life cycle of HK2, specifically addressing how they do, and/or did, replicate.

Indexed as

Anti-HIV AgentsCell Line, TumorEndogenous RetrovirusesGenome, ViralHumansIntegrase InhibitorsLamivudineProtease InhibitorsReverse Transcriptase InhibitorsReverse TranscriptionStavudineVirus ReplicationZidovudineAnti-HIV AgentsIntegrase InhibitorsLamivudineProtease InhibitorsReverse Transcriptase InhibitorsStavudineZidovudineAZTHERV-KNNRTIsNRTIsNtRTIsreverse transcriptase inhibitors

Identifiers

PMID28931682
PMCPMC5686744
OpenAlexW2755096673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.